The decision follows a recent internal strategic review conducted by the prospective partner, which concluded with a prioritization of internal development programs and a realignment of external collaboration initiatives. As a result, no further negotiations toward a binding Research, Development Option and License Agreement will take place.

“We respect our counterpart’s strategic decision and remain confident in the value and potential of our proprietary cyanobacterial cytotoxin payloads for next-generation ADCs,” said Dr Alexis Roberts-McIntosh, CEO of Simris Group. “This outcome does not affect our continued commitment to advancing Simris Biologics’ capabilities and exploring new partnership opportunities in the ADC field and beyond. We continue to pursue our own independent studies internally and in collaboration with our CRO partner.”

Simris Biologics continues to build a robust innovation pipeline targeting oncology and precision therapeutics and remains engaged in multiple ongoing discussions with leading biotech and pharma partners as we generate promising data for our advance payload assets.